<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03840772</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-ERASING</org_study_id>
    <nct_id>NCT03840772</nct_id>
  </id_info>
  <brief_title>Eribulin in Advanced Solitary Fibrous Tumor</brief_title>
  <acronym>ERASING</acronym>
  <official_title>ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Italian, non randomized, open label, multi center, investigator-initiated, Phase&#xD;
      II, clinical study to explore the activity of eribulin in a population of patients with&#xD;
      progressive, advanced (i.e. locally advanced or metastatic), molecularly proven SFT. Patients&#xD;
      with a documented and centrally reviewed pathological diagnosis of locally advanced or&#xD;
      metastatic SFT, and with an evidence of progression within the previous 6 months, may enter&#xD;
      the study.&#xD;
&#xD;
      Study treatments will be administered till progression or toxicity. The primary end-point of&#xD;
      the study is overall response rate Secondary end-points are Progression Free Survival (PFS),&#xD;
      Overall Survival (OS) clinical benefit rate, response rate as by Choi criteria, duration of&#xD;
      response.&#xD;
&#xD;
      Subjects already treated with one or two prior medical therapy regimens for the advanced&#xD;
      phase, whatever agent used in first- or second-line, are eligible for inclusion in the study.&#xD;
      Investigators will consider eligible for this study even patients naïve from chemotherapy,&#xD;
      considering the limited activity of anthracycline in the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Not controlled, single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RECIST 1.1 Overall response rate</measure>
    <time_frame>At week 6</time_frame>
    <description>Proportion of patients with tumor size reduction ⩾ to 30% measured with RECIST Criteria 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choi Response Rate</measure>
    <time_frame>At week 6</time_frame>
    <description>Proportion of patients with tumor size reduction ⩾10% or a decrease in tumour attenuation⩾15% measured with Choi criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Survival from the first eribulin dose to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Survival without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>At week 18</time_frame>
    <description>Proportion of patients with no disease progression after 18 weeks of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the treatment in term of adverse event</measure>
    <time_frame>Week 9, week 18, week 27, week 36</time_frame>
    <description>Safety in term of adverse event is evaluate from the first eribulin dose throughout the study according to CTCAE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Solitary Fibrous Tumor</condition>
  <arm_group>
    <arm_group_label>Eribulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.&#xD;
Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Treatment with eribulin</description>
    <arm_group_label>Eribulin</arm_group_label>
    <other_name>Intervention under investigation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient or legal representative must be able to read and understand the informed&#xD;
             consent form and must have been willing to give written informed consent and any&#xD;
             locally required authorization before any study-specific procedures, including&#xD;
             screening evaluations, sampling, and analyses&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Histological centrally and molecular confirmed diagnosis SFT&#xD;
&#xD;
          4. Locally advanced disease and/or metastatic disease&#xD;
&#xD;
          5. Measurable disease according RECIST 1.1&#xD;
&#xD;
          6. Evidence of progression by RECIST 1.1 during the 6 months before study entry&#xD;
&#xD;
          7. Patients must be treated with at least one prior medical anticancer treatment line for&#xD;
             the advanced phase of disease (both cytotoxic chemotherapy or target treatment&#xD;
             allowed) and with a maximum of 2 lines.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          9. Adequate bone marrow function&#xD;
&#xD;
         10. Adequate organ function&#xD;
&#xD;
         11. Cardiac ejection fraction ≥50%&#xD;
&#xD;
         12. Female patients of child-bearing potential must have negative pregnancy test within 7&#xD;
             days before initiation each cycle of chemotherapy. Post-menopausal women must be&#xD;
             amenorrhoeic for at least 12 months to be considered of non-childbearing potential.&#xD;
             Male and female patients of reproductive potential must agree to employ an effective&#xD;
             method of birth control throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Naïve patients&#xD;
&#xD;
          2. More than 2 lines of anticancer treatment&#xD;
&#xD;
          3. Previous treatment with any other anti-cancer investigational or not investigational&#xD;
             agents within 21 days of first day of study drug dosing,&#xD;
&#xD;
          4. Previous treatment with radiation therapy within 14 days of first day of study drug&#xD;
             dosing, or patients who have not recovered from adverse events due to agents&#xD;
             previously administered&#xD;
&#xD;
          5. Previous radiotherapy to 25% of the bone marrow&#xD;
&#xD;
          6. Major surgery within 21 days prior to study entry&#xD;
&#xD;
          7. Other primary malignancy with &lt;5 years clinically assessed disease-free interval,&#xD;
             except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged&#xD;
             to entail a low risk of relapse&#xD;
&#xD;
          8. Pregnancy or breast feeding&#xD;
&#xD;
          9. Cardiovascular diseases resulting in a New York Heart Association Functional Status &gt;2&#xD;
             . Medical history of a myocardial infarction &lt; 6 months prior to initiation of study&#xD;
             treatment. Unstable angina or myocardial infarction within 6 months of enrolment,&#xD;
             Serious and potentially life-threatening arrhythmia&#xD;
&#xD;
         10. Subjects with a high probability of Long QT Syndrome or corrected QT interval&#xD;
             prolongation of more than or equal to 501 msec , following correction of any&#xD;
             electrolyte imbalance&#xD;
&#xD;
         11. Medical history of arterial thrombotic or embolic events such as cerebrovascular&#xD;
             accident (including transient ischemic attacks), or pulmonary embolism within 6 months&#xD;
             prior to the initiation of study treatment&#xD;
&#xD;
         12. Known history of human immunodeficiency virus infection&#xD;
&#xD;
         13. Active or chronic hepatitis B or C requiring treatment with antiviral therapy&#xD;
&#xD;
         14. Medical history of hemorrhage or a bleeding event ≥ Grade 3 according Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) within 4 weeks prior to the initiation&#xD;
             of study treatment&#xD;
&#xD;
         15. Evidence of any other serious or unstable illness, or medical, psychological, or&#xD;
             social condition, that could jeopardize the safety of the subject and/or his/her&#xD;
             compliance with study procedures, or may interfere with the subject's participation in&#xD;
             the study or evaluation of the study results&#xD;
&#xD;
         16. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in&#xD;
             the formulation of the study drugs&#xD;
&#xD;
         17. Subjects who have not recovered from acute toxicities as a result of prior anti-cancer&#xD;
             therapy to ≤ Grade 1 of CTCAE, except for peripheral neuropathy and alopecia.&#xD;
&#xD;
         18. Pre-existing peripheral neuropathy &gt; CTCAE Grade 2.&#xD;
&#xD;
         19. Expected non-compliance to medical regimens&#xD;
&#xD;
         20. Subjects with known central nervous system metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS INT di Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <phone>0039022390</phone>
    <phone_ext>2803</phone_ext>
    <email>silvia.stacchiotti@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noemi Simone, MD</last_name>
    <phone>0039022390</phone>
    <phone_ext>2803</phone_ext>
    <email>noemi.simone@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <phone>0039091655</phone>
      <phone_ext>4513</phone_ext>
      <email>giuseppebadalamenti@unipa.it</email>
    </contact>
    <contact_backup>
      <last_name>Badalamenti</last_name>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>+3902225411123</phone>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <phone>+39022390</phone>
      <phone_ext>2804</phone_ext>
      <email>silvia.stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Verbeke SL, Fletcher CD, Alberghini M, Daugaard S, Flanagan AM, Parratt T, Kroon HM, Hogendoorn PC, Bovee JV. A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am J Surg Pathol. 2010 Jun;34(6):777-83. doi: 10.1097/PAS.0b013e3181dbedf1.</citation>
    <PMID>20421780</PMID>
  </reference>
  <reference>
    <citation>Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013 Feb;45(2):180-5. doi: 10.1038/ng.2509. Epub 2013 Jan 13.</citation>
    <PMID>23313952</PMID>
  </reference>
  <reference>
    <citation>Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.</citation>
    <PMID>26022454</PMID>
  </reference>
  <reference>
    <citation>Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7. doi: 10.1227/01.NEU.0000325494.69836.51.</citation>
    <PMID>18981882</PMID>
  </reference>
  <reference>
    <citation>Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998 May 15;82(10):1915-20.</citation>
    <PMID>9587125</PMID>
  </reference>
  <reference>
    <citation>Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983 Mar;22(3):167-70. doi: 10.1002/jso.2930220306.</citation>
    <PMID>6682161</PMID>
  </reference>
  <reference>
    <citation>Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.</citation>
    <PMID>23566418</PMID>
  </reference>
  <reference>
    <citation>Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.</citation>
    <PMID>26874885</PMID>
  </reference>
  <reference>
    <citation>Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum In: Lancet Oncol. 2015 Sep;16(9):e427.</citation>
    <PMID>21937277</PMID>
  </reference>
  <reference>
    <citation>Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S, Isu K. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017 Feb 1;47(2):137-144. doi: 10.1093/jjco/hyw175.</citation>
    <PMID>28173193</PMID>
  </reference>
  <reference>
    <citation>Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9. doi: 10.1016/s0959-8049(01)00398-7.</citation>
    <PMID>11872347</PMID>
  </reference>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>September 12, 2023</last_update_submitted>
  <last_update_submitted_qc>September 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solitary Fibrous Tumor</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>rare sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03840772
org study id: ISG-ERASING
nct id: NCT03840772
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin
This is an Italian, non randomized, open label, multi center, investigator-initiated, Phase
      II, clinical study to explore the activity of eribulin in a population of patients with
      progressive, advanced (i.e. locally advanced or metastatic), molecularly proven SFT. Patients
      with a documented and centrally reviewed pathological diagnosis of locally advanced or
      metastatic SFT, and with an evidence of progression within the previous 6 months, may enter
      the study.

      Study treatments will be administered till progression or toxicity. The primary end-point of
      the study is overall response rate Secondary end-points are Progression Free Survival (PFS),
      Overall Survival (OS) clinical benefit rate, response rate as by Choi criteria, duration of
      response.

      Subjects already treated with one or two prior medical therapy regimens for the advanced
      phase, whatever agent used in first- or second-line, are eligible for inclusion in the study.
      Investigators will consider eligible for this study even patients naïve from chemotherapy,
      considering the limited activity of anthracycline in the disease.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Not controlled, single arm study
primary purpose: Treatment
masking: None (Open Label)
measure: RECIST 1.1 Overall response rate
time frame: At week 6
description: Proportion of patients with tumor size reduction ⩾ to 30% measured with RECIST Criteria 1.1
measure: Choi Response Rate
time frame: At week 6
description: Proportion of patients with tumor size reduction ⩾10% or a decrease in tumour attenuation⩾15% measured with Choi criteria
measure: Overall Survival (OS) at 3 years
time frame: At 3 years
description: Survival from the first eribulin dose to death for any cause
measure: Progression Free Survival (PFS) at 3 years
time frame: At 3 years
description: Survival without disease progression
measure: Clinical Benefit Rate
time frame: At week 18
description: Proportion of patients with no disease progression after 18 weeks of therapy.
measure: Safety of the treatment in term of adverse event
time frame: Week 9, week 18, week 27, week 36
description: Safety in term of adverse event is evaluate from the first eribulin dose throughout the study according to CTCAE 5.0
arm group label: Eribulin
arm group type: Experimental
description: Eribulin will be administered at the dose of 1.23 mg/m², intravenously over 2-5 min on day 1 and day 8 of every 21 day cycle.
Study treatment will be administered until evidence of progression or unacceptable toxicity, patient's own willingness, non-compliance or according to clinical investigator's decision.
intervention type: Drug
intervention name: Eribulin
description: Treatment with eribulin
arm group label: Eribulin
other name: Intervention under investigation
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Silvia Stacchiotti, MD
role: Principal Investigator
affiliation: Fondazione IRCCS INT di Milano
last name: Silvia Stacchiotti, MD
phone: 0039022390
phone ext: 2803
email: silvia.stacchiotti@istitutotumori.mi.it
last name: Noemi Simone, MD
phone: 0039022390
phone ext: 2803
email: noemi.simone@istitutotumori.mi.it
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: Italy
citation: Verbeke SL, Fletcher CD, Alberghini M, Daugaard S, Flanagan AM, Parratt T, Kroon HM, Hogendoorn PC, Bovee JV. A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. Am J Surg Pathol. 2010 Jun;34(6):777-83. doi: 10.1097/PAS.0b013e3181dbedf1.
PMID: 20421780
citation: Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013 Feb;45(2):180-5. doi: 10.1038/ng.2509. Epub 2013 Jan 13.
PMID: 23313952
citation: Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.
PMID: 26022454
citation: Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7. doi: 10.1227/01.NEU.0000325494.69836.51.
PMID: 18981882
citation: Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998 May 15;82(10):1915-20.
PMID: 9587125
citation: Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983 Mar;22(3):167-70. doi: 10.1002/jso.2930220306.
PMID: 6682161
citation: Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.
PMID: 23566418
citation: Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.
PMID: 26874885
citation: Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19. Erratum In: Lancet Oncol. 2015 Sep;16(9):e427.
PMID: 21937277
citation: Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S, Isu K. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017 Feb 1;47(2):137-144. doi: 10.1093/jjco/hyw175.
PMID: 28173193
citation: Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002 Mar;38(4):543-9. doi: 10.1016/s0959-8049(01)00398-7.
PMID: 11872347
responsible party type: Sponsor
mesh term: Solitary Fibrous Tumors
mesh term: Hemangiopericytoma
mesh term: Neoplasms, Fibrous Tissue
sharing ipd: No